Determining the Optimal Dose of Tenecteplase Before Endovacular Therapy for Ischaemic Stoke (EXTEND-IA TNK Part 2)
Lead PI: Dr Bruce Campbell
No. of Patients Currently Recruited: No. of Patients Required: 300-656
This study is a prospective, randomised, open-label, blinded endpoint (PROBE) design. Patients who have standard intravenous thrombolysis within 4.5 hours of stoke onset and are assessed for major vessel occlusion may be eligible the trial. Eligible patients who have provided consent will be randomised into either 0.4mg/kg or 0.25mg/kg intravenous tenecteplase before undergoing endovascular thrombectomy.